Quest Diagnostics Incorporated (NYSE:DGX) received a $102.00 price objective from investment analysts at Canaccord Genuity in a report released on Thursday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 10.01% from the stock’s current price.
A number of other research analysts have also commented on DGX. Mizuho increased their price objective on Quest Diagnostics from $86.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, October 21st. Bank of America Corporation restated a “sell” rating and issued a $78.00 price target on shares of Quest Diagnostics in a research report on Monday, November 14th. Barclays PLC set a $85.00 price target on Quest Diagnostics and gave the stock a “hold” rating in a research report on Monday, November 14th. Goldman Sachs Group, Inc. (The) upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $102.00 price target on the stock in a research report on Monday, December 12th. Finally, Zacks Investment Research upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and set a $104.00 price target on the stock in a research report on Monday, January 16th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. Quest Diagnostics presently has a consensus rating of “Hold” and a consensus target price of $90.38.
Quest Diagnostics (NYSE:DGX) opened at 92.72 on Thursday. Quest Diagnostics has a 52-week low of $59.66 and a 52-week high of $95.14. The company’s 50-day moving average price is $92.18 and its 200 day moving average price is $86.17. The firm has a market capitalization of $12.70 billion, a price-to-earnings ratio of 20.56 and a beta of 0.66.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, January 26th. The company reported $1.31 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.04. The firm had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.86 billion. Quest Diagnostics had a return on equity of 14.62% and a net margin of 8.56%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the company earned $1.29 EPS. Equities analysts predict that Quest Diagnostics will post $5.47 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, January 25th. Shareholders of record on Tuesday, January 10th were paid a $0.45 dividend. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend was Friday, January 6th. This represents a $1.80 annualized dividend and a dividend yield of 1.94%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 40.00%.
Several hedge funds have recently added to or reduced their stakes in DGX. Itau Unibanco Holding S.A. bought a new stake in Quest Diagnostics during the third quarter worth about $110,000. TLP Group LLC bought a new stake in Quest Diagnostics during the third quarter worth about $130,000. Pinkerton Retirement Specialists LLC increased its stake in Quest Diagnostics by 792.4% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,651 shares of the company’s stock worth $134,000 after buying an additional 1,466 shares in the last quarter. Pacer Advisors Inc. increased its stake in Quest Diagnostics by 1.5% in the second quarter. Pacer Advisors Inc. now owns 2,458 shares of the company’s stock worth $200,000 after buying an additional 36 shares in the last quarter. Finally, Pennsylvania Trust Co bought a new stake in Quest Diagnostics during the third quarter worth about $204,000. 87.71% of the stock is currently owned by institutional investors and hedge funds.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.